Xingqi Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 599 million yuan, an increase of 105.98%
I'm PortAI, I can summarize articles.
Xingqi Pharmaceutical released its Q3 2025 report, with operating revenue for the first three quarters reaching 1.904 billion yuan, a year-on-year increase of 32.27%; net profit attributable to shareholders was 599 million yuan, a year-on-year increase of 105.98%; net profit excluding non-recurring gains and losses was 596 million yuan, a year-on-year increase of 105.76%; basic earnings per share were 2.44 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments